RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance

RxSight, Inc.

2024-FY EPS reported -$0.71 revenue$139,927,000

Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).
Q4 net loss $(5.9)M vs $(9.2)M; adjusted net earnings $1.3M ($0.03/share) vs adjusted loss $(4.8M).
LAL procedure volume 29,069 units (+61% YoY); LDD installed base 971 (+46% YoY).
FY2025 guidance: revenue $185-197M (32-41% growth), gross margin 71-73%, operating expenses $165-170M.
Cash and investments $237.2M; no debt mentioned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.